BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3503 related articles for article (PubMed ID: 18432410)

  • 1. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia.
    Niller HH; Wolf H; Minarovits J
    Semin Cancer Biol; 2009 Jun; 19(3):158-64. PubMed ID: 19429479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
    Kalla M; Hammerschmidt W
    Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection.
    Callahan J; Pai S; Cotter M; Robertson ES
    Virology; 1999 Sep; 262(1):18-30. PubMed ID: 10489337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic dysregulation of epstein-barr virus latency and development of autoimmune disease.
    Niller HH; Wolf H; Ay E; Minarovits J
    Adv Exp Med Biol; 2011; 711():82-102. PubMed ID: 21627044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
    Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
    Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lytic cycle switches of oncogenic human gammaherpesviruses.
    Miller G; El-Guindy A; Countryman J; Ye J; Gradoville L
    Adv Cancer Res; 2007; 97():81-109. PubMed ID: 17419942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
    Leong IT; Fernandes BJ; Mock D
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
    Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
    AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latency pattern of Epstein-Barr virus and methylation status in Epstein-Barr virus-associated hemophagocytic syndrome.
    Yoshioka M; Kikuta H; Ishiguro N; Endo R; Kobayashi K
    J Med Virol; 2003 Jul; 70(3):410-9. PubMed ID: 12767005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells.
    Niedobitek G; Agathanggelou A; Herbst H; Whitehead L; Wright DH; Young LS
    J Pathol; 1997 Jun; 182(2):151-9. PubMed ID: 9274524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell recognition of Epstein-Barr virus associated lymphomas.
    Rickinson AB; Murray RJ; Brooks J; Griffin H; Moss DJ; Masucci MG
    Cancer Surv; 1992; 13():53-80. PubMed ID: 1330300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.
    Rea D; Fourcade C; Leblond V; Rowe M; Joab I; Edelman L; Bitker MO; Gandjbakhch I; Suberbielle C; Farcet JP
    Transplantation; 1994 Aug; 58(3):317-24. PubMed ID: 8053055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques.
    Blaschke S; Hannig H; Buske C; Kaup FJ; Hunsmann G; Bodemer W
    J Med Virol; 2001 Sep; 65(1):114-20. PubMed ID: 11505452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.
    Delecluse HJ; Feederle R; Behrends U; Mautner J
    Semin Cancer Biol; 2008 Dec; 18(6):409-15. PubMed ID: 18938248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A.
    Seo JS; Cho NY; Kim HR; Tsurumi T; Jang YS; Lee WK; Lee SK
    Oncol Rep; 2008 Jan; 19(1):93-8. PubMed ID: 18097580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus and systemic lupus erythematosus.
    James JA; Harley JB; Scofield RH
    Curr Opin Rheumatol; 2006 Sep; 18(5):462-7. PubMed ID: 16896283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear receptors and their role in Epstein -- Barr virus induced B cell transformation.
    Yenamandra SP; Klein G; Kashuba E
    Exp Oncol; 2009 Jun; 31(2):67-73. PubMed ID: 19550394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of latent membrane protein 2 isoforms in Epstein-Barr virus latency.
    Rechsteiner MP; Bernasconi M; Berger C; Nadal D
    Trends Microbiol; 2008 Nov; 16(11):520-7. PubMed ID: 18835714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latent and lytic Epstein-Barr virus replication strategies.
    Tsurumi T; Fujita M; Kudoh A
    Rev Med Virol; 2005; 15(1):3-15. PubMed ID: 15386591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 176.